

OCT. 18. 2004 1:50PM AVENTIS US PAT DEPT  
TO: US USPTO GENERAL

RECEIVED  
CENTRAL FAX CENTER

NO. 8686 P. 1

OCT 18 2004


PTO/SB/21 (09-04)


Approved for use through 07/31/2006. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/023,933	
	Filing Date	December 21, 2001	
	First Named Inventor	Marc NAZARÉ et al.	
	Art Unit	1621	
	Examiner Name	S. Kumar	
Total Number of Pages in This Submission	12	Attorney Docket Number	DEAV2000/A066 US NP

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC
<input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): <div style="border: 1px solid black; height: 40px; width: 100%;"></div>
<input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	AVENTIS PHARMACEUTICALS INC.	
Signature		
Printed name	Joseph D. Rossi	
Date	October 18, 2004	Reg. No. 47,038

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306 ; Total No. of Pages Transmitted: 12)		
Signature		
Typed or printed name	Paul Irvine	Date October 18, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

OCT. 18. 2004 1:51PM AVENTIS US PAT DEPT

NO. 8686 P. 3

DEAV2000/A066 US NP

RECEIVED  
CENTRAL FAX CENTER

PATENT

OCT 18 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
NAZARE, et al.

Examiner: S. Kumar

Art Unit: 1621

Application No.: 10/023,933

Filed: December 21, 2001

Title: NEW OXYBENZAMIDE  
DERIVATIVES USEFUL FOR  
INHIBITING FACTOR Xa OR VLLa

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, on (703) 872-9306

October 18, 2004

Date of Transmission

Signature

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

REPLY PURSUANT TO 37 CFR § 1.111

In response to the Official Action dated June 16, 2004 ("the Office Action"),  
reconsideration is respectfully requested in view of the amendments and/or remarks as  
indicated below:

- Amendments to the Claims are reflected in the listing of the claims which begins on page 2 of this paper.
- Remarks/Arguments begin on page 8 of this paper.

Filed concurrently herewith is a Petition for Extension of time pursuant to 37 CFR  
§1.136(a) for one (1) month.